Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - ADMA Biologics ( NASDAQ:ADMA ) , Airbnb ( NASDAQ:ABNB )
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Thursday. Shares of Redwire Corporation RDW fell sharply in pre-market trading after the company reported worse-than-expected second-quarter financial results and cut its FY25 sales guidance.
Vaxcyte ( PCVX ) Q2 Loss Widens 11%
Vaxcyte ( NASDAQ:PCVX ) , a biotechnology company specializing in next-generation vaccines, reported its second quarter 2025 results on August 6, 2025. The company reported a GAAP net loss per share of $ ( 1.22 ) , missing the consensus estimate of $ ( 1.16 ) .
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors - Vaxcyte ( NASDAQ:PCVX )
SAN CARLOS, Calif., May 01, 2025 ( GLOBE NEWSWIRE ) -- Vaxcyte, Inc.
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
SAN CARLOS, Calif., May 01, 2025 ( GLOBE NEWSWIRE ) -- Vaxcyte, Inc. ( Nasdaq: PCVX ) , a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran ...
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
SAN CARLOS, Calif., May 01, 2025 ( GLOBE NEWSWIRE ) -- Vaxcyte, Inc. ( Nasdaq: PCVX ) , a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran ...
Corporate America shelled out millions for Trump's inauguration. Now he's upending many of their businesses
Corporations like Target, McDonald's and Delta donated to Trump's inaugural committee after skipping the last two cycles. Now he has roiled their businesses.
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason
The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday - First Watch Restaurant Gr ( NASDAQ:FWRG ) , Delta Air Lines ( NYSE:DAL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Goldman Sachs cut Genuine Parts Company GPC price target from $133 to $114.
Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.
The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet - Corcept Therapeutics ( NASDAQ:CORT ) , Mr. Cooper Gr ( NASDAQ:COOP )
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 100 points on Monday. The Dow traded up 0.30% to 41,710.68 while the NASDAQ fell 1.29% to 17,099.00. The S&P 500 also fell, dropping, 0.41% to 5,557.99. Consumer staples shares jumped by 1.2% on Monday.
Nasdaq Tumbles Over 300 Points; Chicago PMI Rises In March - Corcept Therapeutics ( NASDAQ:CORT ) , Damon ( NASDAQ:DMN )
U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 300 points on Monday. Following the market opening Monday, the Dow traded down 0.27% to 41,473.52 while the NASDAQ fell 1.87% to 16,998.79. The S&P 500 also fell, dropping, 0.91% to 5,530.01.
Trump's Sons Back 'American Bitcoin' With Hut 8; Gold Tops $3,100 Amid Tariff Jitters; Alibaba Expo Boosts US Orders 27% - Top Headlines While The U.S. Slept
Trump Family To Dive Into Bitcoin Mining After DeFi, Meme Coin Projects MARA Holdings Joins GameStop, Metaplanet In Bitcoin Reserve Push With $2 Billion Stock Sale President Trump's Sons Partner With Hut 8 To Unveil American Bitcoin For Large-Scale Bitcoin Mining
Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine - Vaxcyte ( NASDAQ:PCVX )
VAX-24 Mid dose met Phase 2 non-inferiority criteria for 20 of 24 serotypes and showed strong immune responses across all doses. Full post-dose 4 booster data is expected by late 2025, with a Phase 3 infant study planned after VAX-31 Phase 2 data in mid-2026.
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
SAN CARLOS, Calif., March 30, 2025 ( GLOBE NEWSWIRE ) -- Vaxcyte, Inc. ( Nasdaq: PCVX ) , a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call ...
Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive
The European Commission approves MRK's pneumococcal 21-valent conjugate vaccine, Capvaxive, for pneumococcal vaccination in adults.
Collegium Announces Updates to its Board of Directors and Executive Leadership Team
- Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board ...
Collegium Announces Updates to its Board of Directors and Executive Leadership Team - Collegium Pharmaceutical ( NASDAQ:COLL )
- Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board - - Dr. Carlos Paya Nominated to Board of Directors - - New Executives Appointed to Leadership Team.
Market Correction: This Dirt Cheap ETF Is Down by Almost 20%
The benchmark S&P 500 index recently reached correction territory, indicated by a 10% drop from its highs. But certain other parts of the stock market have been hit even harder.One big area of underperformance in the recent market sell-off is small-cap stocks.
3 Driehaus Mutual Funds for Long-term Returns
Invest in Driehaus mutual funds like DVSMX, DMAGX and DRESX for a diversified portfolio.
What's Driving the Market Sentiment Around Vaxcyte? - Vaxcyte ( NASDAQ:PCVX )
Vaxcyte's PCVX short percent of float has fallen 6.6% since its last report. The company recently reported that it has 13.53 million shares sold short, which is 12.32% of all regular shares that are available for trading. Based on its trading volume, it would take traders 10.42 days to cover ...
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 - Vaxcyte ( NASDAQ:PCVX )
SAN CARLOS, Calif., Feb. 12, 2025 ( GLOBE NEWSWIRE ) -- Vaxcyte, Inc. PCVX, a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter ...
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
-- Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- -- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster ...
MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive
The Committee for Medicinal Products for Human Use recommends approval for Merck's pneumococcal 21-valent conjugate vaccine, Capvaxive.
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm - Vaxcyte ( NASDAQ:PCVX )
NEW YORK, Jan. 30, 2025 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vaxcyte, Inc. PCVX breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Trump and Interest Rates: The 2 Key Reasons This Vanguard ETF Could Thrive in 2025
When it comes to the major U.S. stock market indexes, the benchmark S&P 500 ( SNPINDEX: ^GSPC ) tends to get most of the attention. It's highly diversified, but its top eight holdings are the trillion-dollar giants that operate at the forefront of technological innovations such as artificial ...
Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III
SNY begins phase III study for its 21-valent pneumococcal conjugate vaccine for treating invasive pneumococcal disease in infants and toddlers.
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm - Vaxcyte ( NASDAQ:PCVX )
NEW YORK, Dec. 19, 2024 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vaxcyte, Inc. PCVX breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
( PCVX ) - Analyzing Vaxcyte's Short Interest - Vaxcyte ( NASDAQ:PCVX )
Vaxcyte's PCVX short percent of float has risen 13.95% since its last report. The company recently reported that it has 11.03 million shares sold short, which is 10.05% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.9 days to cover their ...
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants - Vaxcyte ( NASDAQ:PCVX )
SAN CARLOS, Calif., Dec. 03, 2024 ( GLOBE NEWSWIRE ) -- Vaxcyte, Inc. PCVX, a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the initiation of the Phase 2 study of VAX-31 in healthy ...
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
-- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster Dose Approximately Nine Months Later -- -- VAX-31 is Designed to Cover Approximately 94% of Invasive ...
( PCVX ) - Analyzing Vaxcyte's Short Interest - Vaxcyte ( NASDAQ:PCVX )
Vaxcyte's PCVX short percent of float has risen 8.49% since its last report. The company recently reported that it has 9.69 million shares sold short, which is 8.82% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.14 days to cover their ...
Should Vanguard Russell 2000 ETF ( VTWO ) Be on Your Investing Radar?
Style Box ETF report for ...
Is it Wise to Retain Alexandria Stock in Your Portfolio Now?
ARE's premium Class A/A+ properties, buyouts and a healthy balance sheet position bode well. A significant development pipeline poses concerns.
Should iShares Russell 2000 Growth ETF ( IWO ) Be on Your Investing Radar?
Style Box ETF report for ...
Should Vanguard Russell 2000 Growth ETF ( VTWG ) Be on Your Investing Radar?
Style Box ETF report for ...
Alexandria Announces Long-Term Lease at San Carlos Mega Campus
ARE announces that it has executed a 10-year lease with Vaxcyte, Inc., a clinical-stage biopharmaceutical company.
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
- Expects to deliver three Investigational New Drug ( IND ) applications in next three years based on next-generation ADC technology ...
1 Vanguard ETF That Could Soar 27.1% Before the End of 2024, According to a Top Wall Street Analyst
This ambitious prediction just received a boost from President-Elect Trump's election win.
Should iShares Russell 2000 ETF ( IWM ) Be on Your Investing Radar?
Style Box ETF report for ...
Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 ( GLOBE NEWSWIRE ) -- Sutro Biopharma, Inc. ( Sutro or the Company ) ( NASDAQ: STRO ) , a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates ( ADCs ) , today announced that REFRαME-P1, the ...
1 Spectacular BlackRock ETF to Buy Ahead of the Russell 2000 Bull Market
Many small-cap stocks have delivered solid returns in 2024, but the benchmark Russell 2000 index is still trading in bear territory.
Peering Into Vaxcyte's Recent Short Interest - Vaxcyte ( NASDAQ:PCVX )
Vaxcyte's PCVX short percent of float has fallen 3.16% since its last report. The company recently reported that it has 9.34 million shares sold short, which is 8.58% of all regular shares that are available for trading. Based on its trading volume, it would take traders 14.17 days to cover their ...
Should iShares Russell 2000 Growth ETF ( IWO ) Be on Your Investing Radar?
Style Box ETF report for ...
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
- 4.3 mg/kg of luveltamab tazevibulin ( luvelta ) in combination with standard dose of bevacizumab ( 15 mg/kg ) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian cancer and was selected to be the recommended phase 2 dose ...
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference - Vaxcyte ( NASDAQ:PCVX )
SAN CARLOS, Calif., Sept. 11, 2024 ( GLOBE NEWSWIRE ) -- Vaxcyte, Inc.
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
SAN CARLOS, Calif., Sept. 11, 2024 ( GLOBE NEWSWIRE ) -- Vaxcyte, Inc. ( Nasdaq: PCVX ) , a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a ...
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN CARLOS, Calif., Sept. 06, 2024 ( GLOBE NEWSWIRE ) -- Vaxcyte, Inc. ( Nasdaq: PCVX ) , a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced ...
Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More
Novavax and Alnylam are in the spotlight following drug approval and regulatory updates, respectively.
Vaxcyte Announces Pricing of $1.3 Billion Public Offering - Vaxcyte ( NASDAQ:PCVX )
SAN CARLOS, Calif., Sept. 04, 2024 ( GLOBE NEWSWIRE ) -- Vaxcyte, Inc. PCVX, a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common ...
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
SAN CARLOS, Calif., Sept. 04, 2024 ( GLOBE NEWSWIRE ) -- Vaxcyte, Inc. ( Nasdaq: PCVX ) , a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public ...
